Matinas BioPharma Hldgs Q2 EPS $(0.02), Inline
Portfolio Pulse from totan@benzinga.com
Matinas BioPharma Holdings (AMEX:MTNB) reported Q2 earnings per share (EPS) of $(0.02), which met analyst expectations. This represents a 33.33% improvement from the $(0.03) per share loss in the same period last year.
August 14, 2024 | 8:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Matinas BioPharma Holdings reported Q2 EPS of $(0.02), meeting analyst expectations and showing a 33.33% improvement from the same period last year.
Meeting analyst expectations and showing a significant improvement in EPS from the previous year is generally positive news for investors. This could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100